Previous close | 34.75 |
Open | 34.75 |
Bid | 22.70 |
Ask | 26.50 |
Strike | 250.00 |
Expiry date | 2024-10-18 |
Day's range | 34.75 - 34.75 |
Contract range | N/A |
Volume | |
Open interest | 40 |
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?
Biogen stock jumped early Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.